Abstract
Is Mesenteric Ischemia in COVID-19 Patients a Surprise?
Talar Vartanoglu Aktokmakyan*, Merve Tokocin, Serhat Meric and Fatih Celebi
Corresponding Author: Talar Vartanoglu Aktokmakyan, General Surgery Department, Istanbul Bagcilar Training and Research Hospital, Merkez Street, Istanbul 34200, Turkey
Accepted: December 12th, 2020
Citation: Aktokmakyan TV, Tokocin M, Meric S & Celebi F. (2020) Is Mesenteric Ischemia in COVID-19 Patients a Surprise? J Infect Dis Res, 3(S3): 28.
Copyrights: ©2020 Aktokmakyan TV, Tokocin M, Meric S & Celebi F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :

Aim: The disease caused by the 2019 novel coronavirus is known predominantly for its respiratory outcomes; a subset of critically ill patients demonstrates clinically remarkable hypercoagulability in which thrombotic events range from acute pulmonary embolism in patients with COVID-19 pneumonia to extremity ischemia. Our observational study aimed to describe the incidence and characteristics, as well as clinical outcomes, of patients presenting and treated for mesenteric ischemia during the COVID-19 pandemic.

Material and Methods: Between March 13 and May 13, 2020, 60 patients operated for emergency reasons were analyzed, and it was noticed that 5 of the 6 COVID-positive patients were operated due to mesenteric ischemia.

Results: Five of sixty patients (83.3%) applied to our emergency clinic with COVID-19 positive and acute abdomen. Two of them (40%) did not have any comorbidities. All of them (%100) were male. There were no complications and only 1 death (20%). Mean leukocyte, neutrophil, and platelet levels were within the normal range, while the lymphocyte level was near the lower limit. C-Reactive Protein was above the limit in all patients. The mean levels of International Normalized Ratio, Platelet, and Activated Partial Thromboplastin Time were above the limits. While D-dimer levels were close to the upper limit; fibrinogen levels were above the normal limit for each patient.

Conclusion: The presence of hypercoagulation status in critical COVID-19 patients should be observed closely, and anticoagulation therapy can be considered in selected patients. More clinical data are needed to examine the role of anticoagulation in COVID-19 treatment.

Keywords: COVID-19, Hypercoagulability, Mesenteric ischemia